Secondary School Madrasas in Bangladesh : Incidence, Quality, and Implications for Reform
No hay miniatura disponible
Fecha
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Washington, DC
Resumen
Descripción
This report presents findings from the
first ever comprehensive survey to document the incidence
and quality of secondary madrasas in Bangladesh. Analysis
also draws upon other publicly available administrative and
household level datasets. Currently the authors have very
little information on school quality in general due to no
national learning assessment system and because schools from
different streams are tested under different Boards. Thus it
is always important to examine the quality of aided madrasas
relative to aided secular schools. The report highlights new
challenges: while gender equality in access has been
achieved in both schools and madrasas, girls remain
systematically disadvantaged in terms of learning outcomes.
The female learning penalty remain is particularly
pronounced in case of madrasas. Overall, the quality of
mathematics and English learning is low in madrasas, but
performance of students of mainstream schools is also
unsatisfactory average quality remains poor across the range
of rural institutions. Overall, this report represents an
empirically grounded investigation into the hitherto
undocumented changes Bangladesh has witnessed in the
secondary madrasa school sector in the past two decades.
Based on their analysis, the authors suggest a range of
policy initiatives that cover the entire secondary education
sector, not just the madarasa education. Given the wealth of
data collected on secondary institutions and households
during the survey, this report only represents the first of
a series of rigorous empirical research and analysis which
will be undertaken. It is hoped that the report will provide
an impetus towards an evidence-based policy debate on
madrasas and other critical issues in the education sector.
Palabras clave
ACCESS TO PHARMACEUTICALS, ACCOUNTABILITY, ACCOUNTING, ACTIVE INGREDIENTS, ANALGESICS, ANTIBIOTICS, ANTIHISTAMINES, BALANCE OF TRADE, BANK FINANCING, BANKRUPTCY, BIOEQUIVALENCE, BIOTECHNOLOGY, BRAND, BRAND NAME, BRAND NAMES, BRANDS, BUDGET ALLOCATION, BUSINESS ENVIRONMENT, BUSINESS OPPORTUNITY, BUSINESS SECTOR, BUYERS, CAPABILITIES, CAPABILITY, CAPACITY BUILDING, CAPITAL STOCK, CAPSULES, CERTIFICATE, CERTIFICATION, COMMERCIAL BANKS, COMMODITY, COMPANY, COMPETITIVE ADVANTAGE, COMPETITIVENESS, CONSUMER MARKET, COPYRIGHT, CORPORATION, CORRUPTION, COUNTERFEIT DRUGS, CURRENCY, DEPRECIATION, DEVELOPING COUNTRIES, DISTRIBUTION CHANNEL, DISTRIBUTION NETWORKS, DOMESTIC MANUFACTURERS, DOMESTIC MARKET, DOMESTIC MARKETS, DOSAGES, DRUG APPROVALS, DRUG CONTROL, DRUG PRICES, DRUG STABILITY, DRUG TESTING, DRUGS, ELECTRICITY, END USER, EQUIPMENT, ESSENTIAL DRUGS, EXPANSION, EXPENDITURES, EXPORT GROWTH, EXPORT MARKET, EXPORT MARKETS, EXPORTER, EXPORTERS, FINANCES, FINISHED PRODUCT, FIXED COSTS, FOREIGN COMPANIES, FOREIGN COMPANY, FOREIGN DIRECT INVESTMENT, FOREIGN MARKETS, FUNCTIONALITY, GENERIC DRUGS, GENERIC PRODUCTS, GLOBAL MARKET, GLOBAL MARKETPLACE, GLOBAL STANDARDS, GLOBAL TRADE, GLOBALIZATION, GMP, GOOD MANUFACTURING PRACTICES, GOVERNMENT FINANCES, GOVERNMENT INTERVENTION, GOVERNMENT POLICY, GROSS DOMESTIC PRODUCT, HEALTH CARE, HERBAL MEDICINES, HOSPITALS, HUMAN DEVELOPMENT, HUMAN RESOURCE, IMMUNIZATION, IMPORT COSTS, INDUSTRIAL DEVELOPMENT, INNOVATION, INSPECTION, INSPECTIONS, INTELLECTUAL PROPERTY, INTELLECTUAL PROPERTY PROTECTION, INTELLECTUAL PROPERTY RIGHTS, INTERNATIONAL BANK, INTERNATIONAL COMPETITIVENESS, INTERNATIONAL DEVELOPMENT, INTERNATIONAL ECONOMICS, INTERNATIONAL FINANCE, INTERNATIONAL LAW, INTERNATIONAL MARKET, INTERNATIONAL MARKETS, INTERNATIONAL STANDARDS, INTERVENTION, INVENTORY, INVENTORY MANAGEMENT, INVESTING, INVESTMENT CAPITAL, INVESTMENT FINANCING, JOINT VENTURE, JOINT VENTURES, LABORATORIES, LACK OF COMPETITION, LAWS, LICENSE, LICENSES, LICENSING, LOCAL INDUSTRY, LOCAL MARKET, MANUFACTURER, MARGINAL COSTS, MARKET SHARE, MARKETING, MARKETPLACE, MATERIAL, MEDICINE, MERGERS, MIDDLEMEN, MNC, MULTINATIONAL, MULTINATIONAL CORPORATION, MULTINATIONAL CORPORATIONS, NDP, NO OBJECTION CERTIFICATE, OPEN MARKET, OUTSOURCING, PACKAGING, PARTY, PATENT ACT, PATENT EXTENSIONS, PATENTS, PHARMACEUTICAL, PHARMACEUTICAL INDUSTRY, PHARMACEUTICAL MANUFACTURERS, PHARMACEUTICAL MANUFACTURING, PHARMACEUTICAL PATENTS, PHARMACEUTICAL PRODUCTION, PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL QUALITY, PHARMACEUTICAL SECTOR, PHARMACEUTICALS, PHARMACIES, PHARMACISTS, PHARMACY, PHYSICAL LOCATION, PORTFOLIO, PRICE CONTROLS, PRIVATE PHARMACIES, PRIVATE SECTOR, PRIVATE SECTOR FIRMS, PROCUREMENT, PRODUCT INFORMATION, PRODUCT QUALITY, PRODUCTIVITY, PROFIT MARGIN, PROFIT MARGINS, PUBLIC HEALTH, PUBLIC MARKET, PURCHASING, QUALITY ASSURANCE, R&D, RAIDS, REGISTRATION FEE, REGISTRATION FEES, REGISTRATION PROCESS, REGULATORY ENVIRONMENT, REGULATORY ENVIRONMENTS, REGULATORY STRUCTURE, RESULT, RESULTS, RETURN, RETURN ON ASSETS, RETURNS, SALE, SALE OF STOCK, SHOPS, SITES, STOCK EXCHANGES, SUBSTITUTE, SUPPLIERS, SUPPLY CHAIN, SURPLUS, TABLETS, TAX, TECHNICAL EXPERTISE, TECHNICAL KNOWLEDGE, TECHNICAL STANDARDS, TECHNICAL TRAINING, TECHNOLOGY TRANSFERS, TOTAL SALES, TRADE BALANCE, TRADEMARK, TRADEMARKS, TRANSPARENCY, TURNOVER, VALUE CHAIN, VIRUS, WAREHOUSE, WAREHOUSES, WHOLESALERS, WORLD TRADE